Bioxytran (BIXT) Cash & Equivalents Growth (1y) (2012 - 2026)
Bioxytran (BIXT) Cash & Equivalents Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 23.56% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.05% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 71.81% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 34.71% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 84.98% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 53.39% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -14.35% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -57.58% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 28.50% |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 7,851.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10,549.66% |
| Dec 31, 2025 | 9,793.56% |
| Sep 30, 2025 | -58.18% |
| Jun 30, 2025 | -76.75% |
| Mar 31, 2025 | -56.62% |
| Dec 31, 2024 | -80.24% |
| Sep 30, 2024 | -56.81% |
| Jun 30, 2024 | -70.07% |
| Mar 31, 2024 | -93.48% |
| Dec 31, 2023 | -91.17% |
| Sep 30, 2023 | -78.55% |
| Jun 30, 2023 | -90.98% |
| Mar 31, 2023 | -79.20% |
| Dec 31, 2022 | 308.25% |
| Sep 30, 2022 | 53.36% |
| Jun 30, 2022 | 29.03% |
| Mar 31, 2022 | 707.10% |
| Dec 31, 2021 | 73.57% |
| Sep 30, 2021 | 38,445.66% |
| Jun 30, 2021 | 9,039.02% |